Pancreatic Cancer Surveillance and Novel Strategies for Screening

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. NCI SEER program cancer stat facts: pancreatic cancer.
        (Available at:) (Accessed June 16, 2021)
        • Rulyak S.J.
        • Brentnall T.A.
        Inherited pancreatic cancer: improvements in our understanding of genetics and screening.
        Int J Biochem Cell Biol. 2004; 36: 1386-1392
        • Giardiello F.M.
        • Offerhaus G.J.
        • Lee D.H.
        • et al.
        Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.
        Gut. 1993; 34: 1394-1396
        • Roberts N.J.
        • Jiao Y.
        • Yu J.
        • et al.
        ATM mutations in patients with hereditary pancreatic cancer.
        Cancer Discov. 2012; 2: 41-46
        • Thompson D.
        • Easton D.F.
        • Breast Cancer Linkage Consortium
        Cancer incidence in BRCA1 mutation carriers.
        J Natl Cancer Inst. 2002; 94: 1358-1365
        • Breast Cancer Linkage Consortium
        Cancer risks in BRCA2 mutation carriers.
        J Natl Cancer Inst. 1999; 91: 1310-1316
        • Goldstein A.M.
        • Fraser M.C.
        • Struewing J.P.
        • et al.
        Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
        N Engl J Med. 1995; 333: 970-974
        • Aarnio M.
        • Mecklin J.P.
        • Aaltonen L.A.
        • et al.
        Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.
        Int J Cancer. 1995; 64: 430-433
        • Jones S.
        • Hruban R.H.
        • Kamiyami M.
        • et al.
        Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
        Science. 2009; 324: 217
        • Hearle N.
        • Schumacher V.
        • Menko F.H.
        • et al.
        Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.
        Clin Cancer Res. 2006; 12: 3209-3215
        • Birch J.M.
        • Alston R.D.
        • McNally R.J.
        • et al.
        Relative frequency and morphology of cancers in carriers of germline TP53 mutations.
        Oncogene. 2001; 20: 4621-4628
        • Klein A.P.
        • Brune K.A.
        • Petersen G.M.
        • et al.
        Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
        Cancer Res. 2004; 64: 2634-2638
        • Brune K.A.
        • Lau B.
        • Palmisano E.
        • et al.
        Importance of age of onset in pancreatic cancer kindreds.
        J Natl Cancer Inst. 2010; 102: 119-126
        • Syngal S.
        • Brand R.E.
        • Church J.M.
        • et al.
        ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes.
        Am J Gastroenterol. 2015; 110: 223-262
        • Stoffel E.M.
        • McKernin S.E.
        • Brand R.
        • et al.
        Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion.
        J Clin Oncol. 2019; 37: 153-164
        • Goggins M.
        • Overbeek K.A.
        • Brand R.
        • et al.
        Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
        Gut. 2020; 69: 7-17
      2. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Version 2.2021.
        (Available at:) (Accessed June 17, 2021)
        • Hall M.J.
        • Bernhisel R.
        • Hughes E.
        • et al.
        Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers.
        Cancer Prev Res. 2021; 14: 433-440
        • Yang X.
        • Leslie G.
        • Doroszuk A.
        • et al.
        Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families.
        J Clin Oncol. 2020; 38: 674-685
        • Brand R.E.
        • Lerch M.M.
        • Rubinstein W.S.
        • et al.
        Advances in counselling and surveillance of patients at risk for pancreatic cancer.
        Gut. 2007; 56: 1460-1469
        • Roch A.M.
        • Schneider J.
        • Carr R.A.
        • et al.
        Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?.
        J Surg Oncol. 2019; 119: 777-783
        • Abe T.
        • Blackford A.L.
        • Tamura K.
        • et al.
        Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance.
        J Clin Oncol. 2019; 37: 1070-1080
        • Bartsch D.K.
        • Slater E.P.
        • Carrato A.
        • et al.
        Refinement of screening for familial pancreatic cancer.
        Gut. 2016; 65: 1314-1321
        • Ariyama J.
        • Suyama M.
        • Satoh K.
        • et al.
        Imaging of small pancreatic ductal adenocarcinoma.
        Pancreas. 1998; 16: 396-401
        • Hruban R.H.
        • Takaori K.
        • Klimstra D.S.
        • et al.
        An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.
        Am J Surg Pathol. 2004; 28: 977-987
        • Tanaka M.
        • Fernandez-del Castillo C.
        • Kamisawa T.
        • et al.
        Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
        Pancreatology. 2017; 17: 738-753
        • Singhi A.D.
        • McGrath K.
        • Brand R.E.
        • et al.
        Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
        Gut. 2018; 67: 2131-2141
        • Canto M.I.
        • Hruban R.H.
        • Fishman E.K.
        • et al.
        Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.
        Gastroenterology. 2012; 142: 796-804
        • Harinck F.
        • Konings I.C.
        • Klujit I.
        • et al.
        A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals.
        Gut. 2016; 65: 1503-1513
        • Vasen H.
        • Ibrahim I.
        • Ponce C.G.
        • et al.
        Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers.
        J Clin Oncol. 2016; 34: 2010-2019
        • Canto M.I.
        • Almario J.A.
        • Schulick R.D.
        • et al.
        Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance.
        Gastroenterol. 2018; 155: 740-751
        • Konings I.C.A.W.
        • Canto M.I.
        • Almario J.A.
        • et al.
        Surveillance for pancreatic cancer in high-risk individuals.
        BJS Open. 2019; 3: 656-665
        • Kogekar N.
        • Diaz K.E.
        • Weinberg A.D.
        • et al.
        Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: a meta-analysis.
        Pancreatology. 2020; 20: 1739-1746
        • Corral J.E.
        • Das A.
        • Bruno M.J.
        • et al.
        Cost-effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis.
        Pancreas. 2019; 48: 526-536
        • Kumar S.
        • Saumoy M.
        • Oh A.
        • et al.
        Threshold analysis of the cost-effectiveness of endoscopic ultrasound in patients at high risk for pancreatic ductal adenocarcinoma.
        Pancreas. 2021;
        • Canto M.I.
        • Kerdsirichairat T.
        • Yeo C.J.
        • et al.
        Surgical outcomes after pancreatic resection of screening-detected lesions in individuals at high risk for developing pancreatic cancer.
        J Gastrointest Surg. 2020; 24: 1101-1110
        • Overbeek K.A.
        • Levink I.J.M.
        • Koopmann B.D.M.
        • et al.
        Long-term yield of pancreatic cancer surveillance in high-risk individuals.
        Gut. 2021;
        • Aslanian H.R.
        • Lee J.H.
        • Canto M.I.
        AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review.
        Gastroenterology. 2020; 159: 358-362
        • Galeotti A.A.
        • Gentiluomo M.
        • Rizzato C.
        • et al.
        Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction.
        J Med Genet. 2021; 58: 369-377
        • Chari S.T.
        • Leibson C.L.
        • Rabe K.G.
        • et al.
        Probability of pancreatic cancer following diabetes: a population-based study.
        Gastroenterol. 2005; 129: 504-511
        • Chen W.
        • Butler R.K.
        • Lustigova E.
        • et al.
        Validation of the enriching new-onset diabetes for pancreatic cancer model in a diverse and integrated healthcare system.
        Dig Dis Sci. 2021; 66: 78-87
        • Sharma A.
        • Kandlakunta H.
        • Nagpal S.J.S.
        • et al.
        Model to determine risk of pancreatic cancer in patients with new-onset diabetes.
        Gastroenterol. 2018; 155: 730-739
      3. A study to establish a new onset hyperglycemia and diabetes cohort.
        (Available at:) (Accessed June 18, 2021)
        • Lowenfels A.B.
        • Maisonneuve P.
        • Cavallini G.
        • et al.
        Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.
        N Engl J Med. 1993; 328: 1433-1437
        • Malka D.
        • Hammel P.
        • Maire F.
        • et al.
        Risk of pancreatic adenocarcinoma in chronic pancreatitis.
        Gut. 2002; 51: 849-852
        • Duell E.J.
        • Lucenteforte E.
        • Olson S.H.
        • et al.
        Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4).
        Ann Oncol. 2012; 23: 2964-2970
        • Tong G.X.
        • Geng Q.Q.
        • Chai J.
        • et al.
        Association between pancreatitis and subsequent risk of pancreatic cancer: a systematic review of epidemiological studies.
        Asian Pac J Cancer Prev. 2014; 15: 5029-5034
        • Greenhalf W.
        • Levy P.
        • Gress T.
        • et al.
        International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the Working Group for the International Consensus Guidelines for Chronic Pancreatitis in conjunction with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club.
        Pancreatology. 2020; 20: 910-918
        • Liu Y.
        • Kaur S.
        • Huang Y.
        • et al.
        Biomarkers and strategy to detect preinvasive and early pancreatic cancer: state of the field and impact of the EDRN.
        Cancer Epidemiol Biomarkers Prev. 2020; 29: 2513-2523
        • Goonetilleke K.S.
        • Siriwardena A.K.
        Systematic review of carbohydrate antigen (CA19-9) as biochemical marker in the diagnosis of pancreatic cancer.
        Eur J Surg Oncol. 2007; 33: 266-270
        • Kim J.
        • Bamlet W.R.
        • Oberg A.L.
        • et al.
        Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
        Sci Transl Med. 2017; 9: eaah5583
        • Kaur S.
        • Smith L.M.
        • Patel A.
        • et al.
        A combination of MUC5AC and CA19-9 improves the diagnosis of pancreatic cancer: a multi-center study.
        Am J Gastroenterol. 2017; 112: 172-183
        • Staal B.
        • Liu Y.
        • Barnett D.
        • et al.
        The sTRA biomarker: blinded validation of improved accuracy over CA19-9 in pancreatic cancer diagnosis.
        Clin Cancer Res. 2019; 25: 2745-2754
        • Jahan R.
        • Ganguly K.
        • Smith L.M.
        • et al.
        Trefoil factor(s) and CA19-9: a promising panel for early detection of pancreatic cancer.
        EBioMedicine. 2019; 42: 375-385
      4. A study of IMMRayTM PanCan-d test for early detection of pancreatic cancer in high-risk groups.
        (Available at:) (Accessed June 18, 2021)
        • Mellby L.D.
        • Nyberg A.P.
        • Johansen J.S.
        • et al.
        Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer.
        J Clin Oncol. 2018; 36: 2887-2894
        • Cohen J.D.
        • Javed A.A.
        • Thoburn C.
        • et al.
        Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.
        Proc Natl Acad Sci U S A. 2017; 114: 10202-10207
        • Cohen J.D.
        • Lu L.
        • Wang Y.
        • et al.
        Detection and localization of surgically resectable cancers with a multi-analyte blood test.
        Science. 2018; 359: 926-930
        • Chu L.C.
        • Park S.
        • Kawamoto S.
        • et al.
        Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue.
        AJR Am J Roentgenol. 2019; 213: 349-357
        • Machicado J.D.
        • Koay E.J.
        • Krishna S.G.
        Radiomics for the diagnosis and differentiation of pancreatic cystic lesions.
        Diagnostics (Basel). 2020; 10: 505